Imaging colon cancer response following treatment with AZD1152: A preclinical analysis of [18F]fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]fluorothymidine imaging

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1099-1110

  Moroz, Maxim A ^a   Kochetkov, Tatiana ^a   Cai, Shangde ^a   Wu, Jiyuan ^a   Shamis, Mikhail ^a   Nair, Jayasree ^a   De Stanchina, Elisa ^a   Serganova, Inna ^a   Schwartz, Gary K ^a   Banerjee, Debabrata ^b   Bertino, Joseph R ^b   Blasberg, Ronald G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BARASERTIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; METHOTREXATE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; KI-67 ANTIGEN; METHOTREXATE; MICE; MICE, NUDE; PHOSPHORIC ACID ESTERS; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOPHARMACEUTICALS; THYMIDINE; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952265709     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1430     Document Type: Article

References (52)

1. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-48. (Pubitemid 351471713)
2. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004;301:60-7. (Pubitemid 39388897)
3. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
4. Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 1999;274:7334-40.
5. Gautschi O, Mack PC, Davies AM, Lara PN Jr, Gandara DR. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer 2006;8:93-8. (Pubitemid 44596750)
6. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24.
7. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40. (Pubitemid 47443920)
8. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140:295-302.
9. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8. (Pubitemid 46955132)
10. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93:662-9. (Pubitemid 351669305)
11. Dancey JE. Kinase Inhibitor 4 Minisymposium summary. Expert Rev Anticancer Ther 2009;9:891-4.
12. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69:4150-8.
13. Nair JS, de Stanchina E, Schwartz GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009;15:2022-30.
14. Hopert A, Uphoff CC, Wirth M, Hauser H, Drexler HG. Specificity and sensitivity of polymerase chain reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell lines. J Immunol Methods 1993;164:91-100.
15. Humm JL, Lee J, O'Donoghue JA, et al. Changes in FDG tumor uptake during and after fractionated radiation therapy in a rodent tumor xenograft. Clin Positron Imaging 1999;2:289-96.
16. Huhnt W, Lubbe AS. Growth, microvessel density and tumor cell invasion of human colon adenocarcinoma under repeated treatment with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995;121:423-8.
17. Lalor PA, Mapp PI, Hall PA, Revell PA. Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody, Ki67. Rheumatol Int 1987;7:183-6.
18. Kim EJ, Yoo JY, Choi YH, Ahn KJ, Lee JD, Yun CO, et al. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy. Yonsei Med J 2008;49:811-8.
19. Guda K, Natale L, Markowitz SD. An improved method for staining cell colonies in clonogenic assays. Cytotechnology 2007;54:85-8. (Pubitemid 47174825)
20. Barnes MJ, Estlin EJ, Taylor GA, Aherne GW, Hardcastle A, McGuire JJ, et al. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin Cancer Res 1999;5:2548-58. (Pubitemid 29437341)
21. Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol 2009;64:1053-8.
22. Roper PR, Drewinko B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 1976;36:2182-8.
23. Magro PG, Russo AJ, Li WW, Banerjee D, Bertino JR. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Res 2004;64:4338-45. (Pubitemid 38802441)
24. Carling D, Aguan K, Woods A, Verhoeven AJ, Beri RK, Brennan CH, et al. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. J Biol Chem 1994;269:11442-8. (Pubitemid 24200360)
25. Carling D. The role of the AMP-activated protein kinase in the regulation of energy homeostasis. Novartis Found Symp 2007;286:72-81; discussion -5, 162-3, 96-203.
26. Barnes BR, Zierath JR. Role of AMP-activated protein kinase in the control of glucose homeostasis. Curr Mol Med 2005;5:341-8. (Pubitemid 40663139)
27. Braiman L, Alt A, Kuroki T, Ohba M, Bak A, Tennenbaum T, et al. Protein kinase Cdelta mediates insulin-induced glucose transport in primary cultures of rat skeletal muscle. Mol Endocrinol 1999;13:2002-12. (Pubitemid 30637262)
28. Bradshaw HD, Jr . Molecular cloning and cell cycle-specific regulation of a functional human thymidine kinase gene. Proc Natl Acad Sci U S A 1983;80:5588-91.
29. Conrad AH, Ruddle FH. Regulation of thymidylate synthetase activity in cultured mammalian cells. J Cell Sci 1972;10:471-86.
30. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′- deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992;36:808-18.
31. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-67. (Pubitemid 40326566)
32. Baukelien van Triest HMP, van Hensbergen Y, Smid K, Smid K, Telleman F, Schoenmakers PS, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clinical Cancer Research 1999;5:643-54. (Pubitemid 29131976)
33. Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007;6:3147-57.
34. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;Suppl:96S-103S.
35. Buck AK, Bommer M, Juweid ME, Glatting G, Stilgenbauer S, Mottaghy FM, et al. First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med 2008;49:1756-62.
36. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055-61. (Pubitemid 44877006)
37. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 003;44:1426-31.
38. Buck AK, Herrmann K, Buschenfelde CM, Juweid ME, Bischoff M, Glatting G, et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res 2008;14:2970-7.
39. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-9.
40. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003;30:1407-12. (Pubitemid 37247960)
41. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
42. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47. (Pubitemid 47312585)
43. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82. (Pubitemid 43073435)
44. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 2007;34:1003-11. (Pubitemid 46919556)
45. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31:720-4.
46. Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol 2008;10:271-80.
47. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55.
48. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008;49:186-94. (Pubitemid 351225655)
49. vanWestreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005;46:400-4.
50. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401. (Pubitemid 43289860)
51. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525-33. (Pubitemid 41214194)
52. KennyLM,ContractorKB, StebbingJ,Al-Nahhas A,Palmieri C,Shousha S, et al. Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics inhuman breast cancer followingcapecitabinetreatmentdetected by positron emission tomography. Clin Cancer Res 2009;15:6649-57.